688236 Beijing Chunlizhengda Medical Instruments
- 20.48
- -0.89-4.16%
Beijing Chunlizhengda Medical Instruments News
Express News | Science and Technology Innovation Board review: Composite fluid collection concept stocks are collectively active, and Haimxing's 20CM rose or stopped
Express News | Chunli Medical's offer leaked out from the national procurement site for artificial joints
Express News | Everbright Securities: Demand for medical devices and scientific instruments is expected to expand
Zhongtai Securities: Steady performance under the influence of policies and fundamentals, grasping investment opportunities driven by medical device innovation+ inflection points
The medical device industry continues to grow rapidly. It is optimistic about importation substitution and global development driven by innovation. Volume procurement policies will continue to be implemented, medical anti-corruption is expected to ease, and sector valuations are expected to gradually recover.
Express News | Science and Technology Innovation Board Review: The Science and Technology Innovation 50 Index closed down 1.01%, and aerospace concept stocks surged
Changes in Hong Kong stocks | Chunli Healthcare (01858) is now up more than 5%, joint tender renewal document No. 2 issued, and the company's hip reports rank among the highest
Chunli Healthcare (01858) is now up more than 5%. As of press release, it is up 5.18% to HK$12.18, with a turnover of HK$10.394 million.
Chunli Medical (688236): Better hip coverage is expected, knee replacement is expected
The joint procurement contract renewal policy was announced, and Chunli Medical ranked first in hip reports. On April 30, 2024, the National Health Insurance Administration issued a continuous procurement document for artificial joint collection. We think Chunli Medical: 1) The hip joint coverage is relatively good this time, domestically produced
春立醫療：2024年第一季度報告
春立醫療：2023 年報
Chunli Medical (688236.SH) announced first-quarter results, net profit of 55.2 million yuan, a year-on-year decrease of 1.18%
Chunli Medical (688236.SH) disclosed its report for the first quarter of 2024. The company achieved revenue of 2.2 during the reporting period...
Chunli Healthcare (688236): Performance growth is affected by policies, optimistic about subsequent recovery
1Q24 policy factors affect the performance growth rate of the company's 1Q24 operating income/net profit/net profit deducted from non-net profit of 222/0.55/ 0.49 billion yuan, -10.0%/-1.2%/-1.5% year-on-year. 1Q24
The medical device sector rebounded underwater. Wanfu Biotech rose more than 11%, Yahuilong rose more than 6%, and many stocks such as Chunli Healthcare and Jet Biotech followed suit.
The medical device sector rebounded underwater. Wanfu Biotech rose more than 11%, Yahuilong rose more than 6%, and many stocks such as Chunli Healthcare and Jet Biotech followed suit.
Chunli Medical (01858.HK) plans to hold a board meeting on April 29 to approve the first quarter results
Gelonghui, April 17, 丨 Chunli Healthcare (01858.HK) issued an announcement. The board of directors will hold a board meeting on April 29, 2024 (Monday) to approve (among others) the announcement of the first quarter results of the company and its subsidiaries for the three months ended March 31, 2024 and consider paying an interim dividend (if any).
Guoxin Securities released a research report on April 10 stating that it gave Chunli Healthcare (688236.SH) a purchase rating. The main reasons for the rating include: 1) the performance was partially affected by collection, and net profit fell 9.7% in 20
Guoxin Securities released a research report on April 10 stating that it gave Chunli Healthcare (688236.SH) a purchase rating. The main reasons for the rating include: 1) the performance was partially affected by collection, and net profit fell 9.7% in 2023; 2) the growth of joint products was slightly pressured, and overseas business revenue increased sharply; 3) gross net margin declined slightly, and sales and R&D expenses were steadily declining; 4) operating cash flow performance improved significantly; 5) intensive R&D investment, and the product pipeline was constantly being enriched. (Mainichi Keizai Shimbun)
Chunli Healthcare (688236): Cash flow improved significantly year on year, overseas revenue increased by 82% year on year
The performance was partly affected by collection, and overseas business revenue increased dramatically. In 2023, it achieved revenue of 1,209 million yuan (+0.6%), net profit attributable to mother of 278 million yuan (-9.7%), net profit after deducting non-return to mother of 255 million (-
Chunli Medical (688236) Annual Report Review: Short-term performance is affected by collection, and recovery is expected to accelerate in 24 years
Incident: The company released its annual results report for 23 years, achieved revenue of 1,209 billion yuan (+0.6%) for the whole year, achieved net profit attributable to shareholders of listed companies of 278 million yuan (-9.7%), and realized net profit of 250 million yuan (-9.7%) after deducting non-return to mother
Chunli Medical (688236) 2023 Report Review: Collection affects 23-year performance with high overseas business growth
Matters: The company released its 2023 annual report, with revenue of 1,209 million yuan (+0.58%), net profit to mother of 278 million yuan (-9.72%), and net profit after deducting non-net profit of 255 million yuan (-8.32%).
Chunli Medical (688236): The impact of collection is gradually clear, and overseas business expansion is accelerating
Key investment events: The company released its 2023 annual report and achieved revenue of 1,209 million yuan in 2023 (+0.58%, year-on-year growth rate, same below); net profit to mother of 278 million yuan (-9.72%); deducted from non-government
CHUNLI MEDICAL To Go Ex-Dividend On July 2nd, 2024 With 0.39918 HKD Dividend Per Share
March 31st - $CHUNLI MEDICAL(01858.HK)$ is trading ex-dividend on July 2nd, 2024. Shareholders of record on July 3rd, 2024 will receive 0.39918 HKD dividend per share on July 31st, 2024. The ex-di
Chunli Healthcare (688236): Significant improvement in cash flow, outstanding overseas performance
Key investment points: Maintain an increase in holdings rating. Based on industry conditions, the 2024-2025 EPS forecast was slightly lowered to 0.92/1.21 yuan (originally 0.95/1.25 yuan), and the 2026 forecast EPS was added to
Analysis
Price Target
No Data
